Literatur
- 1
Advanced Colorectal Cancer Meta-Analysis Project .
Modulation of fluorouracil by leucovorin in patients with
advanced colorectal cancer: evidence in terms of response rate.
J
Clin
Oncol.
1992;
10
896-903
- 2
Carmichael J, Polpiela T, Radstone D, Falk S, Fey M, Oza A, Skovsgaard T, Martin C.
Randomized comparative study of ORZEL (oralUracil/Tegafur
(UFT) plus leucovorin (LV)) versus parenteral 5-fluorouracil (5-FU) plus LV in
patients with metastatic colorectal cancer.
Proc
ASCO.
1999;
18
264
- 3
Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U,
Garin A, Graeven U, McKendrick J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G,
Rosso R, Rougier P, Schilsky R L.
First-line oral capecitabine therapy in metastatic colorectal
cancer: a favourable safety profile compared with intravenous
5-fluorouracil/leucovorin.
Ann
Oncology.
2002;
13
566-575
- 4
Hoff P M, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C,
Harrison E, Burger H U, Osterwalder B, Wong A O, Wong R.
Comparison of oral capecitabine versus intravenous
fluorouracil plus leucovorin as first-line treatment in 605 patients with
metastatic colorectal cancer: results of a randomised phase III
study.
J Clin
Oncol.
2001;
19
2282-2292
- 5
Meta-analysis Group in Cancer .
Efficacy of intravenous continuous infusion of fluorouracil
compared with bolus administration in advanced colorectal cancer.
J
Clin
Oncol.
1998;
16
301-308
- 6
Pazdur R, Douillar J Y, Skillings J R, Eisenberg P D, Davidson N, Harper P, Vincent M D,
Lembersky B C, Benner S E.
Multicenter phase III study of 5-fluorouracil (5-FU) or UFT
in combination with leucovorin (LV) in patients with metastatic colorectal
cancer.
Proc
ASCO.
1999;
18
263a
- 7
Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E,
Reigner B.
Preferential activation of capecitabine in tumor following
oral administration to colorectal cancer patients.
Cancer Chemother
Pharmacol.
2000;
45
291-297
- 8
Sulkes A, Benner S E, Canetta R M.
Uracil-Ftorafur: an oral fluoropyrimidin active in colorectal
cancer.
J Clin
Oncol.
1998;
16
3461-3475
- 9
Twelves C. on behalf of the Xeloda Colorectal Cancer Group .
Capecitabine as first-line treatment in colorectal cancer:
pooled data from two large, phase III trials.
Eur J
Cancer.
2002;
38
S15-S20
- 10
Twelves C J, Cassidy J.
Which endpoints should we use in evaluating the use of novel
fluoropyrimidine regimens in colorectal cancer.
Br J
Cancer.
2002;
86
1670-1676
- 11
Van Cutsem E, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, Cassidy J, Dirix L,
Twelves C, Seitz J F, Schölmerich J, Burger H U, Verweij J.
Capecitabine, an oral fluoropyrimidine carbamate with
substantial activity in advanced colorectal cancer: results of a randomised
phase II study.
J Clin
Oncol.
2000;
18
1337-1345
- 12
Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M,
Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P,
Schmiegel W H, Seitz J F, Thompson P, Vieitez J M, Weitzel C, Harper P. for the Xeloda
Colorectal Cancer Study Group .
Oral capecitabine compared with intravenous fluorouracil plus
leucovorin in patients with metastatic colorectal cancer: results of a large
phase III study.
J Clin
Oncol.
2001;
19
4097-4106
Prof. Dr. med. R. Porschen
Klinik für Innere Medizin, Zentralkrankenhaus Bremen
Ost
Züricher Straße 40
28325 Bremen
